Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12762663 | 1.00 | PPM1B (0.41) | PPM1BPTPN1PPP1CCCYP2C19POLB | |
| SCHEMBL12762683 | 0.88 | PPM1B (0.37) | PPM1BPTPN1PPP1CCCYP2C19CYP2D6 | |
| SCHEMBL18800248 | 0.88 | PPM1B (0.37) | PPM1BPTPN1PPP1CCCYP2C19CYP2D6 | |
| SCHEMBL19115098 | 0.84 | PPM1B (0.34) | PPM1BPTPN1PPP1CCPOLB | |
| SCHEMBL12762665 | 0.80 | — | — | |
| SCHEMBL18118607 | 0.79 | ALDH1A1 (0.44) | PTPN1CYP2C19POLBCYP2D6ALDH1A1 | |
| SCHEMBL12762646 | 0.79 | MEN1 (0.31) | PPM1BPTPN1PPP1CCPOLBMEN1 | |
| SCHEMBL19532419 | 0.78 | — | — | |
| SCHEMBL25836269 | 0.78 | FABP7 (0.47) | CYP2C19POLBCYP2D6ALDH1A1MEN1 | |
| SCHEMBL12762677 | 0.78 | PPM1B (0.31) | PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702632-B2 | Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease | UNIVERSITY OF MASSACHUSETTS (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702632-B2 | Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease | ICOS, CD4, NFATC1 | PPM1B 1765/4885PTPN1 99/4885PPP1CC 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.